07:00 , May 19, 2014 |  BC Week In Review  |  Company News

Aslan, CSL deal

Aslan gained worldwide rights to CSL334 ( ASLAN004 ) from CSL. The human mAb against IL-13 receptor alpha 1 ( IL-13RA1 ; IL-13Ra ; CD213A1 ) is in preclinical testing to treat asthma. Aslan will...
07:00 , May 19, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Kythera Biopharmaceuticals Inc. (NASDAQ:KYTH) gained $1.85 to $33.22 last week after submitting an NDA to FDA for deoxycholic acid (ATX-101) to reduce submental (under chin) fat. Kythera plans to submit ex-U.S. regulatory applications...
01:30 , May 14, 2014 |  BC Extra  |  Company News

Aslan gains rights to preclinical asthma product from CSL

Aslan Pharmaceuticals Pte. Ltd. (Singapore) gained worldwide rights to CSL334 from CSL Ltd. (ASX:CSL). The human mAb against IL-13 receptor alpha 1 (IL-13RA1; IL-13Ra; CD213A1) is in preclinical testing to treat asthma. Aslan will fund...